Hansen N, Ågerstam H, Wahlestedt M, Landberg N, Askmyr M, Ehinger M, Rissler M, Lilljebjörn H, Johnels P, Ishiko J, Melo JV, Alexander WS, Bryder D, Järås M, Fioretos T. SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function.
Leukemia 2012;
27:130-5. [PMID:
22824785 PMCID:
PMC3542906 DOI:
10.1038/leu.2012.169]
[Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
Suppressor of cytokine signaling 2 (SOCS2) is known as a feedback inhibitor of cytokine
signaling and is highly expressed in primary bone marrow (BM) cells from patients with
chronic myeloid leukemia (CML). However, it has not been established whether SOCS2 is
involved in CML, caused by the BCR/ABL1 fusion gene, or important for normal
hematopoietic stem cell (HSC) function. In this study, we demonstrate that although
Socs2 was found to be preferentially expressed in long-term HSCs,
Socs2-deficient HSCs were indistinguishable from wild-type HSCs when challenged
in competitive BM transplantation experiments. Furthermore, by using a retroviral
BCR/ABL1-induced mouse model of CML, we demonstrate that SOCS2 is
dispensable for the induction and propagation of the disease, suggesting that the
SOCS2-mediated feedback regulation of the JAK/STAT pathway is deficient in
BCR/ABL1-induced CML.
Collapse